Clearmind Medicine Achieves Nasdaq Compliance
Clearmind Medicine Inc. (NASDAQ: CMND), a clinical-stage biotech firm, proudly announces that it has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement. This milestone marks a significant achievement for the company, which focuses on developing groundbreaking neuroplastogen-derived therapeutics aimed at addressing major health issues.
Details of Compliance Notification
The notification from Nasdaq, received on December 10, 2025, was based on the company's recent Form 6-K, submitted on December 5, 2025. As part of Nasdaq's Listing Rule 5550(b)(1), companies are required to maintain a minimum stockholders' equity of $2,500,000. Clearmind's compliance ensures its continued listing on this prestigious exchange.
Ongoing Monitoring and Future Compliance
Being back in compliance is a remarkable step, yet the journey continues. Nasdaq has confirmed that it will monitor Clearmind's equity status closely in the future. Failure to demonstrate compliance in the next periodic report could lead to potential delisting, underscoring the importance of maintaining strong financial health.
Innovative Approach to Health Challenges
Clearmind is at the forefront of the psychedelic pharmaceutical industry, dedicated to researching and creating novel therapeutics that can address underserved health issues. The company's focus includes conditions such as alcohol use disorder, where traditional treatments have often fallen short. By exploring psychedelic-derived compounds, Clearmind aims to discover effective new treatments that can significantly improve patients' quality of life.
Intellectual Property Portfolio
The strength of Clearmind's development efforts is reflected in its robust intellectual property portfolio, which currently encompasses nineteen patent families and a total of 31 granted patents. The company remains proactive in seeking additional patents for its innovative compounds, ensuring a competitive edge in the market.
Market Presence and Trading Information
Clearmind's shares are actively traded on Nasdaq under the ticker symbol "CMND" as well as on the Frankfurt Stock Exchange with the symbol “CWY0.” This dual listing showcases the firm's commitment to reaching a global audience as it advances its unique therapeutic solutions.
Contact Information for Investors
For further inquiries or investor relations, individuals can reach out via email or telephone. The company encourages communication and fosters transparency with its investors. Contact details include:
Investor Relations
Email: invest@clearmindmedicine.com
Telephone: (604) 260-1566
Frequently Asked Questions
What recent compliance achievement did Clearmind Medicine announce?
Clearmind Medicine announced it has achieved compliance with Nasdaq's minimum stockholders' equity requirement.
What is the minimum stockholders' equity requirement for Nasdaq?
The minimum equity requirement is set at $2,500,000 for companies listed on Nasdaq.
What are Clearmind's main areas of focus in therapeutic development?
Clearmind focuses on developing psychedelic-derived therapeutics to tackle significant health issues, including alcohol use disorder.
How many patents does Clearmind currently hold?
Clearmind possesses a portfolio of nineteen patent families, with a total of 31 granted patents.
Where can investors find more information about Clearmind Medicine?
Investors can visit Clearmind's official website at www.clearmindmedicine.com for more information.
